Inhalable Insulin


Also found in: Wikipedia.
A formulation of insulin—Exubera—that was marketed in the US in 2006–2007, but withdrawn by Pfizer because of its high price and dosing imprecision; other drug companies are developing inhalable insulins
References in periodicals archive ?
collaborated to launch Afrezza (insulin human) Inhalation Powder, inhalable insulin.
Separately, Riccardo Perfetti, senior medical officer for diabetes at Sanofi, briefed analysts on launch plans for inhalable insulin Afrezza.
I am reminded of this because the FDA recently approved MannKind's inhalable insulin product, Afrezza.
So might something that was in the news last month: the decision by an FDA advisory panel to approve Afrezza, an inhalable insulin produced by MannKind Corporation, for clinical trials.
He shows managers and leaders tools to create a strategy to build and shape innovation ecosystems and illustrates those that failed and succeeded, such as Nokia's 3G handset that failed to profit because partners in its ecosystem did not complete their innovations in time; Pfizer's inhalable insulin, which failed when endocrinologists wouldn't allow the requirement of lung function testing; Michelin's tires designed to run for 125 miles after a blowout, impacted by a failure in understanding the way in which service centers would adopt the solution; and successes like Amazon, Hasbro, and Apple.
But history is littered with great products that never quite made it, from electric cars to inhalable insulin to any e-reader that came out before the Kindle.
New York, NY) said that the United States District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera, in the United States.
It dispenses a dry powder, synthesized insulin called Exubera, the first inhalable insulin for the mass market.
The Valencia biotech selling its inhalable insulin called Afrezza, the firm's sole commercial product, and the diabetes research organization will collaborate to decide if Afrezza can be used in the medicine of children as well as advance new treatments in diabetes care.
NEW YORK -- New systemic formulations that will enable the delivery of inhalable insulin and other high-market drugs should provide a major market leap for pulmonary drug delivery.
Whilst there have been marginal improvements in injectable devices - insulin "pens" - the recent approval of inhalable insulin is the first step to opening new opportunities in the non-invasive delivery of this life-giving macromolecule.
Our cover story details a new process to make an inhalable insulin that's convenient to use.